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Massive bleeding during childbirth kills
more than 100,000 women worldwide
each year. Blood loss kills a vast num-
ber of accident victims before they can
reach a trauma center. Loss of blood is
also blamed for 50% of deaths on the
battlefield. Prompt transfusionof blood
could prevent most of these deaths.
Unfortunately, since the life-giving fluid
has to be kept refrigerated and needs
to be typed and cross-matched before
use, it is rarely available in ambulances
or in combat situations. And with a
growing population accompanied by
a decline in blood collection, even the
best-equipped hospitals are not im-
mune to shortages. Any catastrophic
event such as an earthquake or a
terrorist attack could rapidly exhaust
available supplies.
Blood shortages in developing coun-
triesareparticularly acute, according to
the World Health Organization. These
nations account for more than 80% of
the world’s population, yet collect less
than 35% of the global blood supply.
Safety standards there are often lower
aswell. TheUnitedStatesandotherde-
veloped countries have come a long
way since the 1980s, when thousands
of hemophiliacs died from receiving
HIV-tainted blood products. But more
than 70 developing countries still
don’t test all their donated blood for
HIV, hepatitis, or syphilis. ‘‘Blood is in
short supply, and theblood that is avail-
able is often unsafe,’’ says Harvey
Klein, who heads the department of
transfusionmedicine at the National In-
stitutes of Health (NIH). ‘‘A substitute
that doesn’t need typing and doesn’t
transmit disease would be invaluable.’’
These considerations give new ur-
gency to the search for a blood sub-
stitute—or more correctly, an artificial
oxygen carrier. Scientists have known
since the 19th century that a protein
in red blood cells (RBCs), hemoglobin,
is essential for oxygen transport. Early
attempts in the1930s to transfusea so-
lution of purified cell-free hemoglobin
largely failed. It was only in the 1950s
that scientists discovered the protein’s
molecular structure: a tetramer con-
sisting of four polypeptide chains,
each equipped with a heme unit that
can bind to an oxygen molecule. With
about 250million of these oxygen-hun-
gry molecules packed into each of the
25 trillion RBCs in a human body, he-
moglobin is the key to an amazingly
effective system that delivers the right
amountof oxygen to tissuesat all levels
of activity.
Outside the RBC, however, the he-
moglobinmolecule is lesswell behaved:
it enters blood vessel walls, causing
over-oxygenation and reduction of the
nitric oxide level that maintains blood
vesselwalls ina relaxedstate.The result
is vasoconstriction—a narrowing of
arteries and capillaries that causes
blood pressure to shoot up. Free hemo-
globin also generates reactive oxygen
species such as hydrogen peroxide
and superoxide ions that damage cells
and tissues. Furthermore, hemoglobin
molecules outside RBCs rapidly break
down into dimers highly toxic to the kid-
ney, as was observed in the first human
safety trial of free hemoglobin in 1978.
To make a more stable compound,
a common strategy is to crosslink re-
active amino groups that lie on the he-
moglobin molecule’s surface. Cross-
links within the molecule can prevent
it from breaking down into toxic di-
mers, but not from getting into blood
vessel walls. Products based on this
approach, such as Baxter’s HemAs-
sist, have fared poorly in human trials
and have largely been abandoned.
Crosslinks across molecules, on the
other hand, result in large polyhemo-
globin aggregates that don’t infiltrate
vascular walls as easily. Examples of
these so-called second-generation
oxygen carriers are Northfield Labora-
tories’ PolyHeme and Hemosol’s He-
molink, both based on human hemo-
globin, and Biopure’s Hemopure,
based on bovine hemoglobin. All three
products have shown mixed results in
human trials; while they reduce the
need for blood transfusion, they seem
to increase the risk of cardiovascular
and other problems. ‘‘The good news
is that they deliver oxygen effectively,’’
says Klein. ‘‘But they show disturbing
evidence of toxicity.’’
In addition to posing safety con-
cerns, the products are challenging
to manufacture because they require
extraction, purification, and modifica-
tion of hemoglobin. Further, the raw
material in most cases is either cow’s
blood, which might raise disease con-
cerns, or expired human blood, which
is dwindling in supply.
Fluorocarbonemulsionsareapoten-
tial alternative to hemoglobin. Devel-
oped initially during the Manhattan
Project as an inert buffer material for
handling corrosive uranium isotopes,
fluorocarbons turned out to be good
solvents for oxygen. In adramaticdem-
onstration, scientists showed in 1966
thatmice immersed in an oxygen-satu-
rated fluorocarbon liquid could survive
for up to ten minutes. As oxygen car-
riers, fluorocarbons offer several ad-
vantages: they are nontoxic, use easily
available rawmaterials, and are simple
to manufacture. ‘‘We just put a handful
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an emulsion,’’ says Thomas Drees,
president andCEOof Sanguine, a fluo-
rocarbon manufacturer. ‘‘The process
is not capital or labor intensive.’’
Although less toxic thanhemoglobin,
fluorocarbons are not problem free.
They can provoke the complement
system, affect platelet function, and
potentially cause strokes. And unlike
hemoglobin-based products, which
can deliver oxygen very effectively un-
der physiologic conditions, fluorocar-
bon-based carriers require the patient
to breathe oxygen-enriched air. ‘‘The
bulk of evidence suggests that a hemo-
globin-based carrier is more likely to
come to market,’’ says Klein.
Both classes of product have shown
mixed results in clinical trials. HemAs-
sist showed promise in early studies,
but in Phase III trials it seemed to
increase mortality rates. Baxter sus-
pended a Phase III trial of the product
in 1998 because of adverse outcomes.
Hemolink fared similarly: although one
Phase III trial demonstrated its effec-
tiveness in reducing blood transfusion
needs, another Phase IIb trial of the
product was suspended in 2003 be-
cause of increased incidence of heart
problems. A Phase III trial completed
in Europe in 2002 showed that Oxy-
gent, a fluorocarbon-based carrier
made by Alliance, could effectively
reduce blood transfusion needs during
surgery. However, another Phase III
trial of this product in the U.S. ended
early in 2001 because of an apparent
increase in the risk of stroke. In a Phase
III trial of Hemopure completed in
2002, nearly 60% of surgery patients
getting the product did not need any
blood transfusions at all. However,
safety concerns caused FDA to reject
Biopure’s 2006 proposal for a Phase
III trial of the product for hemorrhagic
shock. (At present Hemopure is ap-
proved in South Africa; in the U.S,
a low-grade version is available for
veterinary use.) And in a recently com-
pleted Phase III trial by Northfield Lab-
oratories, trauma victims infused with
PolyHeme, which performed well in
earlier, smaller human studies, fared
worse than controls who got saline fol-
lowed by blood. Such setbacks have
landed many of the manufacturers in
serious financial difficulty.1092 Chemistry & Biology 14, October 20Many of these failures can be attrib-
uted to poor study design, says Jona-
than Jahr, an anesthesiologist at the
University of California, Los Angeles,
who has led five clinical trials of oxy-
gen carriers. Jahr points out that no
pathway currently exists for indepen-
dent investigators to obtain and study
these products, and he urges the Food
and Drug Administration (FDA) and the
NIH to rectify this situation. ‘‘Other-
wise, companies rush into clinical trials
without a product that was validated in
the first place,’’ he says.
Some companies express frustra-
tion with regulatory policies. ‘‘Safety
standards kept creeping up as you
went towards a trial,’’ says David Bell,
vice president of drug development
at Hemosol, referring to the suspended
2003 Hemolink clinical trial. ‘‘You
started to move away from the true
benefit of the product and started fo-
cusing on the risks.’’ For instance, reg-
ulators may require a product de-
signed to resuscitate trauma victims
in the field, where blood is typically
unavailable, to be at least as safe as
blood, since it couldpotentiallybeused
‘‘off-label’’ in a different setting. Such
requirements are a challenge for the in-
dustry, agrees Jahr. ‘‘A head-to-head
comparison with blood is the worst-
case scenario for an oxygen carrier,’’
he says. Regulatory officials, however,
argue that their task is complicated by
the scientific complexity of oxygencar-
riers. Inherent product toxicities and
lack of adequately predictive animal
models make it ‘‘difficult to judge the
relative benefits and risks of proposed
trials,’’ says Jay Epstein, director of the
Office of Blood Research and Review
at the FDA.
While existing oxygen carriers await
regulatory approval, some companies
are making ‘‘third-generation’’ prod-
ucts that modify hemoglobin in new
ways. Examples are Hemosol’s HRC
101, which attaches a starch polymer
to the hemoglobin molecule; Sangart’s
Hemospan, which affixes strands of
polyethylene glycol to the molecule;
and Oxyvita’s Oxyvita, a polymerized
hemoglobin made without crosslinks.
While HRC 101 and Oxyvita are in the
preclinical stage, Hemospan is in
Phase III trials in Europe for use during
surgery. According to the manufac-07 ª2007 Elsevier Ltd All rights reservedturers, preliminary results are promis-
ing: the new products are less toxic
and don’t constrict blood vessels as
much. ‘‘We’ve tuned the oxygen re-
lease parameters so that the capillaries
are open and flowing and oxygen is
delivered to tissue,’’ says Robert Win-
slow, Sangart’s president and CEO.
What will be the commercial poten-
tial for an oxygen carrier, once it is
licensed? That depends on the appli-
cation, says Eugene Trogan, biotech-
nology analyst for the investment
banking firm Morgan Joseph. For situ-
ations where blood is unavailable,
such as field resuscitation, Trogan es-
timates the U.S. market to be about
$150 million per year. But if the prod-
uct replaces blood in the 1.8 million
transfusions that are given each year,
the market could exceed a billion dol-
lars, he says. A longer shelf life and
the lack of a typing/cross-matching re-
quirement would, in theory, make such
a product attractive. To access this
larger market, however, the product
would need to be at least as safe as
blood. It would also need to last for
a reasonably long time in the human cir-
culation; current products, unfortu-
nately, work only for a few days,
whereas a RBC circulates for nearly
four months. ‘‘This field has a tremen-
dous potential in the marketplace,’’
says Trogan. ‘‘The problem is that it
hasbeenmiredwithclinicaldifficulties.’’
Leading oxygen carrier manufac-
turers have spent $150–$500 million
in research and development, Trogan
estimates. Given this outlay, the prod-
ucts may cost $500–$1000 per unit, 2–
4 times more than blood. The price tag
may deter their use where they are
most needed: in the developing world,
where blood is often either unavailable
or unsafe. ‘‘If you can’t afford to test for
HIV, you probably can’t afford to buy
a blood substitute,’’ says Klein.
Despite past setbacks, manufac-
turers of oxygen therapeutics remain,
well, sanguine. They are confident that
their products will soon surmount the
scientific and regulatory hurdles and
succeed commercially. ‘‘It’s a very ex-
citing time,’’ says Winslow. ‘‘I think we
are getting close to the finish line here.’’
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